기사

[Medical Today = Reporter Min-seok Choi]

Cell therapy specialist Prodizen announced on the 3rd that it successfully participated in IMCAS World Congress 2026, held in Paris, France.

IMCAS World Congress is one of the most influential international academic events in the fields of dermatology, plastic surgery, and aesthetic medicine. More than 10,000 medical professionals and industry stakeholders from over 150 countries attend the event each year. Along with exhibition booths, the congress features academic sessions, live demonstrations, and workshops, serving as a practical platform for technical exchange and a key global stage where new products and technologies are internationally validated.

At IMCAS 2026, Prodizen attracted significant attention from local medical professionals and buyers by unveiling its flagship product, sPRP, for the first time in the European market under the name “DP Plasma Power,” through its official European distributor, Dermapen World.

DP Plasma Power is designed to maximize platelet recovery rates and to stably extract high-purity PRP in a short amount of time. Known domestically as “sPRP,” the product has already received high evaluations in orthopedics, dermatology, and regenerative medicine in Korea. Through its participation in IMCAS, Prodizen directly showcased the technology and stability of DP Plasma Power to European medical professionals and buyers.

A Prodizen official stated, “As IMCAS is a venue where medical experts from around the world directly evaluate technology, this participation and launch carried significance beyond a simple exhibition,” adding, “Through the European-oriented brand DP Plasma Power, we plan to expand our presence in the European market at an even faster pace.”

Meanwhile, since its establishment in 1998, Prodizen has secured its position as a technology-driven company in the field of regenerative medicine by becoming the first in Korea to successfully localize PRP kits. The company manages the entire production process in-house through its own GMP-certified manufacturing facilities and focuses on developing customized solutions tailored to medical environments across the United States, Europe, the Middle East, and Asia, based on its high-concentration PRP extraction technology.

Medical Today, Reporter Min-seok Choi (press@mdtoday.co.kr